

Fatal bacteremia caused by Pantoeaagglomerans in a critically ill patient.

Karakosta P MD, Agaliadou-Dioritou U MD, PhD, Aslanidis Th MD, PhD

ABSTRACT

Fatal bacteremia caused by Pantoeaagglomerans in a critically ill patient.

Karakosta P, Agaliadou-Dioritou U, Aslanidis Th

We present a case report concerning fatal bacteremia caused by *Pantoeaagglomerans* in a critically ill patient.

INTRODUCTION

Pantoea is a genus of *Enterobacteriaceae* Gram-negative bacteria family that includes at least 20 species; mostly isolated in the ecological niches. Data about its role as pathogen are limited¹. μορφών.

CASE REPORT

A 65 year old female, was admitted to our Intensive Care Unit (ICU) after developing acute respiratory failure due to septic shock following 4 days hospitalization in internal medicine department for community acquired pneumonia. Her medical history included morbid obesity (BMI 55.1 kg. m⁻²), smoking (50 pack-years), chronic obstructive pulmonary disease, arterial

hypertension and depression; all under medication, however with bad compliance. On admission her Acute Physiology, Age, Chronic Health Evaluation IV score (APACHE IV) score was 129.

During her 107 days ICU hospitalization, the patient developed series of septic episodes with several microorganisms isolated from various samples (Table 1).

Antibiotic and supportive therapy strategy followed, managed successfully all spotted infections; yet, the patient died 9 days after *Pantoeaagglomerans* bacteraemia and even though antibiogram revealed a sensitive strain. Concurrent laboratory examination for any possible medical equipment *Pantoea* contamination turned out negative.

Intensive Care Unit, St. Paul General Hospital, Thessaloniki, Greece

Table1. Isolated bacteria during patient's hospitalization, along with location spotted, selected laboratory results and antibiotic regimen followed.

DATE	BACTERIA	SOURCE	WBC	CPR	PCT	ANTIBIOTIC	MIC
04/02/2019	-	-	19.4	12.7	0.2	moxifloxacin	Emp.th
						clarithromycin	Emp.th
08/02/2019	Ac.baum.	bs	53.3	40.6	17.5	colistin	<0.5
	Ac.baum.	blood				colistin	<0.5
						teicoplanin	Emp.th
20/02/2019	Ac.baum.	blood	17.1	2.3	0.4	colistin	<0.5
	Stlulg	blood					
	E.faecalis	blood				linezolid	2
21/02/2019	Ac.baum.	bs	15.63	2.7	0.19	colistin	<0.25
25/02/2019	M morg	blood	14.08	8.8	0.34	meropenem	<0.25
	Psaer	cvc					
	Ac.baum.	cvc					
27/02/2019	Psaer(MBL)	bs	10.9	10.7	0.8	colistin	<0.5
	Ac.baum.	bs				colistin	<0.5
03/03/2019	Prst	cvc	7.9	34	1.27		
	St. haem	cvc				voncon	1
06/03/2019	St. haem	blood	7.	16	0.99	voncon	1
15/03/2019	Pr. mir.	bs	8.99	11.3	0.34	amikacin	<2
	Prst	bs				amikacin	<2
21/03/2019	Kl. pn.		13.5	5	0.21	amikacin	<2
22/03/2019	Ps.aer/Ac.bau	bs	16.02	8	0.24	colistin	<0.25
	Ac.baum.	cvc					
27/03/2019	Psaer(MBL)	bs	14.200	15.3	0.61	colistin	<0.5
15/04/2019	Prst	bs	15.100	18	0.49	aztreonam	2
	Ac.baum.					meropenem	<0.25
27/04/2019	Ac.baum.	p ulcer	11430	5.8	0.5	colistin	<0.5
	Kl. pn.	p ulcer				gentamicin	<1
02/05/2019	Ac.baum.	cvc	11820	15.3	0.29	colistin	<0.5
						tigecycline	8
09/05/2019	Pantoeaspp.	blood	9.690	13.6	0.21	ciprofloxacin	<0.25

WBC: white blood count ($k/\mu L$), CPR:C-reactive protein (mg/dl), PCT: procalcitonin (ng/dl), MIC: minimum inhibitory concentration, Ac.baum: *Acinetobacter baumanii*, St.lugd: *Staphylococcus lugdonensis*, E.faecalis:*Enterococcus faecalis*, M.morg: *Morganella morganii*, Ps. aer: *Pseudomonas aeruginosa*, Kl.pn: *Klebsiella pneumoniae*, St. haem: *Staphylococcus haemolyticus*, Pr.mir:*Proteusmirabilis*, Pr.st: *Providencia stuartii*, CVC: central venous catheter, bs: bronchial secretions, p ulcer: pressure ulcer, Emp.th: empiric therapy.

In most literature reports the clinical course of the hospital-acquired disease was mild and application of the proper antibiotic treatment led to full recovery¹. Fatal cases are mainly described with in epidemics of nosocomial septicemia caused by contamination of medical equipment or fluids². Most of the reports regard pediatric population, especially newborns³⁻⁴, while data about similar adult cases are limited⁵⁻⁶. The present case is presumably due to the decline of patients' immunity caused by underlying disease and/or hospital procedures. Other *Pantoeaspp* identified as pathogens in adults is *Pantoea dispersa*⁷⁻⁸. Nevertheless, in the era of multiresistant bacteria, similar reports alert clinicians about the possibility of more frequent emerge of this type of infections.

REFERENCES

1. Cruz AT, Cazacu AC, Allen CH. *Pantoeaagglomerans*, a plant pathogen causing human disease. *J Clin Microbiol.* 2007;45(6):1989-92.
2. Dutkiewicz J, Mackiewicz B, Lemieszek M, et al. *Pantoeaagglomerans*: A mysterious bacterium of evil and good. Part III. Deleterious effects: Infections of humans, animals and plants. *Ann Agric Environ Med* 2016; 23(2):197-205.
3. Segado-Arenas A, Alonso-Ojembarrena A, Lubián-López SP, et al. *Pantoeaagglomerans*: a new pathogen at the neonatal intensive care unit? *Arch Argent Pediatr.* 2012;110(4):e77-9.
4. Panknin HT. An outbreak of fatal *pantoea* infections in newborn infants, caused by contaminated infusion solutions. *Kinderkrankenschwester.* 2006; 25(5):189-90.
5. Kurşun O, Unal N, Cesur S, et al. A case of ventilator-associated pneumonia due to *Pantoeaagglomerans*. *Mikrobiyol Bul.* 2012; 46(2): 295–298 (in Turkish).
6. Izzo I, Lania D, Castro A, et al. Seven cases of port-a-cath contamination caused by *Pantoeaagglomerans* in the Oncological Service of Iseo Hospital, Brescia (Italy). *Infez Med.* 2014; 22(2): 152–155.
7. Asai N, Koizumi Y, Yamada A, et al. *Pantoea dispersa* bacteraemia in an immunocompetent patient: a case report and review of the literature. *J Med Case Rep.* 2019;13(1):33.
8. Panditrao M, Panditrao M. *Pantoea dispersa*: Is it the Next Emerging "Monster" in our Intensive Care Units? A Case Report and Review of Literature. *Anesth Essays Res.* 2018 ;12(4):963-6.

Keywords: bacteremia, pantoeaagglomerans, intensive care unit

Author Disclosures:

Authors Karakosta P, Agaliadou-Dioritou U and Aslanidis Th have no conflicts of interest or financial ties to disclose.

Corresponding author:

Paschalia Karakosta,
3 Viopoulou str, PC 55132,
Thessaloniki, Greece.
tel: +306945491151,
email:pas.karakosta@yahoo.gr